<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Series C</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Storm raises $56M series C for phase II RNA inhibitor trial in sarcoma</title>
      <description>
        <![CDATA[RNA epigenetics specialist Storm Therapeutics Ltd. has closed a $56 million series C to fund phase II development of its lead RNA enzyme inhibitor, STC-15, in treating myo- and liposarcomas, and announced that the first patient has been treated in the trial.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730390</guid>
      <pubDate>Thu, 16 Apr 2026 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730390-storm-raises-56m-series-c-for-phase-ii-rna-inhibitor-trial-in-sarcoma</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Blue-dollar-sign-on-white-background.webp?t=1721252292" type="image/jpeg" medium="image" fileSize="39433">
        <media:title type="plain">Blue dollar sign on white background</media:title>
      </media:content>
    </item>
    <item>
      <title>Science Corp. raises $230M for Prima BCI retinal implant</title>
      <description>
        <![CDATA[Science Corp. raised $230 million in an oversubscribed series C financing round to commercialize its Prima brain-computer interface (BCI) retinal implant and to advance other pipeline programs into the clinic. The investment brings the company’s total funding, since founding in 2021, to approximately $490 million and shows investors growing appetite for BCI technologies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729346</guid>
      <pubDate>Thu, 05 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729346-science-corp-raises-230m-for-prima-bci-retinal-implant</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/PRIMA-22oct24.webp?t=1772740430" type="image/jpeg" medium="image" fileSize="353671">
        <media:title type="plain">PRIMA implant</media:title>
        <media:description type="plain">Prima implant. Credit: Science Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Polares raises $50M for mitral valve system</title>
      <description>
        <![CDATA[Polares Medical SA raised $50 million in a series C financing round for Mrace, its posterior leaflet replacement system designed to treat mitral regurgitation. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/729301</guid>
      <pubDate>Wed, 04 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729301-polares-raises-50m-for-mitral-valve-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/cardio-heart-mitral-valve.webp?t=1611181711" type="image/png" medium="image" fileSize="397941">
        <media:title type="plain">3D rendering of heart, mitral valve</media:title>
      </media:content>
    </item>
    <item>
      <title>Automata secures $45M in series C raise</title>
      <description>
        <![CDATA[Automata Technologies Ltd. raised $45 million in a series C funding round that included a strategic investment partnership with Danaher Corp. The funds will be used to support the scaling of customer deployments, the building of the next generation of Automata’s data and closed-loop experimentation software platform and the expansion of its global operations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728283</guid>
      <pubDate>Fri, 30 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728283-automata-secures-45m-in-series-c-raise</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Automata-LINQ-bench-lab-7-19.webp?t=1769800731" type="image/jpeg" medium="image" fileSize="179566">
        <media:title type="plain">Automata LINQ bench lab</media:title>
        <media:description type="plain">Automata Linq bench lab</media:description>
      </media:content>
    </item>
    <item>
      <title>Oricell raises $70M series C to advance China-developed CAR Ts</title>
      <description>
        <![CDATA[Oricell Therapeutics Holdings Ltd. announced a $70 million series C1 round to expand its global footprint and speed clinical development of its CAR T therapies. The round was co-led by Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners and a leading global health care fund.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727883</guid>
      <pubDate>Tue, 13 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727883-oricell-raises-70m-series-c-to-advance-china-developed-car-ts</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Cancer-Chimeric-Antigen-Receptor-CAR-T-Cell.webp?t=1691077403" type="image/jpeg" medium="image" fileSize="249886">
        <media:title type="plain">3D rendering of CAR T therapy in cell</media:title>
      </media:content>
    </item>
    <item>
      <title>Tubulis smashes series C European record with $356M raised</title>
      <description>
        <![CDATA[Antibody-drug conjugate specialist Tubulis GmbH has raised a hefty €308 million (US$356 million) series C to expand clinical development of TUB-040, positioning its lead program for use in additional indications and as an earlier line of therapy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725079</guid>
      <pubDate>Wed, 15 Oct 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725079-tubulis-smashes-series-c-european-record-with-356m-raised</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/Dominik-Schumacher-CEO-Tubulis-10-15.webp?t=1760554700" type="image/jpeg" medium="image" fileSize="398354">
        <media:title type="plain">Dominik Schumacher, co-founder and CEO, Tubulis</media:title>
        <media:description type="plain">Dominik Schumacher, co-founder and CEO, Tubulis</media:description>
      </media:content>
    </item>
    <item>
      <title>Full-Life nabs $77M for radiopharmaceuticals, Belgium GMP site </title>
      <description>
        <![CDATA[Full-Life Technologies Ltd. announced Sept. 29 the completion of a $77 million financing, comprising $50 million in series C equity and $27 million in debt financing, which will be used to advance a portfolio of radiopharmaceuticals and radionuclide-drug conjugates worldwide.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725020</guid>
      <pubDate>Tue, 07 Oct 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725020-full-life-nabs-77m-for-radiopharmaceuticals-belgium-gmp-site</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/3D-dollar-sign.webp?t=1624487200" type="image/png" medium="image" fileSize="316216">
        <media:title type="plain">3D dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Full-Life nabs $77M for radiopharmaceuticals, Belgium GMP site </title>
      <description>
        <![CDATA[Full-Life Technologies Ltd. announced Sept. 29 the completion of a $77 million financing, comprising $50 million in series C equity and $27 million in debt financing, which will be used to advance a portfolio of radiopharmaceuticals and radionuclide-drug conjugates worldwide.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724639</guid>
      <pubDate>Wed, 01 Oct 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724639-full-life-nabs-77m-for-radiopharmaceuticals-belgium-gmp-site</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/3D-dollar-sign.webp?t=1624487200" type="image/png" medium="image" fileSize="316216">
        <media:title type="plain">3D dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Iantrek raises $42M for Alloflo Uveo glaucoma therapy launch</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[Iantrek Inc. reported the close of a $42 million series C financing round, which it said will facilitate the U.S. commercial launch of its Alloflo Uveo, a bio-interventional ophthalmic surgery solution targeting the lightly used uveoscleral pathway, as well as broader pipeline expansion.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723439</guid>
      <pubDate>Wed, 27 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723439-iantrek-raises-42m-for-alloflo-uveo-glaucoma-therapy-launch</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Iantrek-alloflo-uveo-27aug25.webp?t=1756331032" type="image/jpeg" medium="image" fileSize="113012">
        <media:title type="plain">Iantrek Alloflo Uveo</media:title>
        <media:description type="plain">Iantrek Alloflo Uveo. Credit: Iantrek</media:description>
      </media:content>
    </item>
    <item>
      <title>Ultromics raises $55M for AI platform to tackle heart failure</title>
      <description>
        <![CDATA[Ultromics Ltd. raised $55 million in a series C financing round to expand its commercial footprint across the U.S. and invest in the development of new AI modules for earlier, more accurate detection of cardiovascular disease, Ross Upton, CEO and founder of Ultromics told <em>BioWorld</em>.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722561</guid>
      <pubDate>Thu, 31 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722561-ultromics-raises-55m-for-ai-platform-to-tackle-heart-failure</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Dollar-sign-between-hands.webp?t=1740610521" type="image/jpeg" medium="image" fileSize="123345">
        <media:title type="plain">Dollar sign between hands</media:title>
      </media:content>
    </item>
    <item>
      <title>Polyactiva raises $25M series C to advance U.S. clinical programs</title>
      <description>
        <![CDATA[Ophthalmology company Polyactiva Pty Ltd closed a AU$40 million (US$25 million) series C round to advance late-stage clinical trials in the U.S. of its lead candidate, PA-5108.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721833</guid>
      <pubDate>Tue, 01 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721833-polyactiva-raises-25m-series-c-to-advance-us-clinical-programs</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Polyactiva-implant-25june25.webp?t=1750886384" type="image/jpeg" medium="image" fileSize="463813">
        <media:title type="plain">Polyactiva implant</media:title>
        <media:description type="plain">Polyactiva’s ocular implants are two millimeters long and .2 mm in diameter. Credit: Polyactiva</media:description>
      </media:content>
    </item>
    <item>
      <title>Polyactiva raises $25M series C to advance U.S. clinical programs</title>
      <description>
        <![CDATA[Ophthalmology company Polyactiva Pty Ltd closed a AU$40 million (US$25 million) series C round to advance late-stage clinical trials in the U.S. of its lead candidate, PA-5108.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721713</guid>
      <pubDate>Wed, 25 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721713-polyactiva-raises-25m-series-c-to-advance-us-clinical-programs</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Polyactiva-implant-25june25.webp?t=1750886384" type="image/jpeg" medium="image" fileSize="463813">
        <media:title type="plain">Polyactiva implant</media:title>
        <media:description type="plain">Polyactiva’s ocular implants are two millimeters long and .2 mm in diameter. Credit: Polyactiva</media:description>
      </media:content>
    </item>
    <item>
      <title>Safeheal secures €35M for endoluminal fecal bypass system</title>
      <description>
        <![CDATA[Safeheal SAS raised €35 million (US$39.72 million) in an oversubscribed series C financing round for its temporary endoluminal fecal bypass system, Colovac, which is placed in the colon following colorectal resection. The funds will be used to complete an investigational device exemption pivotal study and speed up preparation for commercial launch of the device.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719643</guid>
      <pubDate>Wed, 07 May 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719643-safeheal-secures-35m-for-endoluminal-fecal-bypass-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/colon-cancer-cell.webp?t=1588881323" type="image/png" medium="image" fileSize="447411">
        <media:title type="plain">Colon cancer illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Deepull raises €50M for bloodstream infection test</title>
      <description>
        <![CDATA[Deepull Diagnostics SL raised €50 million (US$56.93 million) in an oversubscribed series C financing round to complete clinical validation studies of its UllCORE diagnostic system for direct-from-blood rapid pathogen detection.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719539</guid>
      <pubDate>Thu, 01 May 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719539-deepull-raises-50m-for-bloodstream-infection-test</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/sepsis-bacteria-blood.webp?t=1745260750" type="image/jpeg" medium="image" fileSize="307255">
        <media:title type="plain">Blood cells and bacteria</media:title>
      </media:content>
    </item>
    <item>
      <title>Glycomine snags $115M to advance its PMM2-CDG treatment</title>
      <description>
        <![CDATA[Glycomine Inc. secured $115 million in a series C financing round to support the advancement of GLM-101 into a phase IIb study in patients with phosphomannomutase-2 congenital disorder of glycosylation (PMM2-CDG).]]>
      </description>
      <guid>http://www.bioworld.com/articles/719289</guid>
      <pubDate>Thu, 17 Apr 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719289-glycomine-snags-115m-to-advance-its-pmm2-cdg-treatment</link>
    </item>
    <item>
      <title>Brainomix raises £14M for AI-powered imaging solution for stroke, lung fibrosis</title>
      <description>
        <![CDATA[Brainomix Ltd. raised £14 million ($18 million) in a series C financing round to expand its AI-powered imaging solution, Brainomix 360 Stroke, into the U.S. market. Funds will also go towards advancing the Brainomix 360 E-Lung, which can accurately predict the progression of lung fibrosis. “This series C round is a vital fundraise for us,” Michalis Papadakis, CEO and co-founder of Brainomix, told BioWorld. “We are in a growth stage where we want to bring this next generation of stroke AI into the U.S. market.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/717993</guid>
      <pubDate>Thu, 20 Mar 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/717993-brainomix-raises-14m-for-ai-powered-imaging-solution-for-stroke-lung-fibrosis</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Brainomix-360-E-aspects-software-3-20.webp?t=1742505795" type="image/jpeg" medium="image" fileSize="555642">
        <media:title type="plain">Brainomix 360 Stroke platform</media:title>
        <media:description type="plain">Brainomix 360 Stroke platform. Credit: Brainomix Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Harrison.ai raises AU$179M in series C round to fuel global expansion</title>
      <description>
        <![CDATA[Harrison.ai raised AU$179 million (US$112 million) in a series C round to expand its radiology and pathology solutions across the U.S., Europe, the Middle East, Africa and Asia Pacific.]]>
      </description>
      <guid>http://www.bioworld.com/articles/717640</guid>
      <pubDate>Tue, 18 Feb 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/717640-harrisonai-raises-au179m-in-series-c-round-to-fuel-global-expansion</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Australian-bills.webp?t=1719432949" type="image/jpeg" medium="image" fileSize="257308">
        <media:title type="plain">Australian money</media:title>
      </media:content>
    </item>
    <item>
      <title>Harrison.ai raises AU$179M in series C round to fuel global expansion</title>
      <description>
        <![CDATA[Harrison.ai raised AU$179 million (US$112 million) in a series C round to expand its radiology and pathology solutions across the U.S., Europe, the Middle East, Africa and Asia Pacific.]]>
      </description>
      <guid>http://www.bioworld.com/articles/716937</guid>
      <pubDate>Fri, 14 Feb 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/716937-harrisonai-raises-au179m-in-series-c-round-to-fuel-global-expansion</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Australian-bills.webp?t=1719432949" type="image/jpeg" medium="image" fileSize="257308">
        <media:title type="plain">Australian money</media:title>
      </media:content>
    </item>
    <item>
      <title>Radiopharma Advancell raises $112M in series C for alpha therapies</title>
      <description>
        <![CDATA[Aussie radiopharma company Advancell Co. Ltd. closed an oversubscribed $112 million series C round that will accelerate clinical development of its pipeline of radionuclide therapies and allow it to expand its manufacturing capacity.]]>
      </description>
      <guid>http://www.bioworld.com/articles/716961</guid>
      <pubDate>Tue, 04 Feb 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/716961-radiopharma-advancell-raises-112m-in-series-c-for-alpha-therapies</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/Advancell-Alpha-212-2-4.webp?t=1738700086" type="image/jpeg" medium="image" fileSize="62151">
        <media:title type="plain">Vial of Advancell's Alpha-212 isotope</media:title>
        <media:description type="plain">Alpha 212 is the isotope Lead-212 and powers Advancell's therapeutic pipeline. Credit: Advancell Co. Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Cornerstone Robotics raises $70M to expand international footprint</title>
      <description>
        <![CDATA[Cornerstone Robotics Ltd. raised more than $70 million in a series C round to expand its international footprint and accelerate R&D efforts for its robotic surgery solutions.&nbsp;<span style=" font-style: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; widows: 2; word-spacing: 0px; display: inline !important; float: none;">The funds will allow the Hong Kong-headquartered company to accelerate commercialization of new surgical robotic products, conduct clinical trials, obtain regulatory approvals and promote global adoption of advanced robotic surgical solutions. </span>
]]>
      </description>
      <guid>http://www.bioworld.com/articles/715979</guid>
      <pubDate>Tue, 14 Jan 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/715979-cornerstone-robotics-raises-70m-to-expand-international-footprint</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Cornerstone-Robotics-Sentire-14jan25.webp?t=1736892217" type="image/jpeg" medium="image" fileSize="124041">
        <media:title type="plain">Cornerstone Robotics Sentire</media:title>
        <media:description type="plain">Sentire endoscopic robot. Credit: Cornerstone Robotics Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Precision Neuroscience raises $102M for AI-powered BCI technology</title>
      <description>
        <![CDATA[Precision Neuroscience Corp. recently raised $102 million in a series C funding round for its AI-powered brain–computer interface (BCI) technology, the Layer 7 Cortical Interface. The funding comes as interest in the technology heats up as clinical trials show that BCI devices are capable of transforming the lives of people with disabilities.]]>
      </description>
      <guid>http://www.bioworld.com/articles/715223</guid>
      <pubDate>Thu, 19 Dec 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/715223-precision-neuroscience-raises-102m-for-ai-powered-bci-technology</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Layer-7-Cortical-Interface-19dec24.webp?t=1734702556" type="image/jpeg" medium="image" fileSize="179251">
        <media:title type="plain">Layer 7 Cortical Interface</media:title>
        <media:description type="plain">Layer 7 Cortical Interface. Credit: Precision Neuroscience</media:description>
      </media:content>
    </item>
    <item>
      <title>Caresyntax raises $180M to grow precision surgery platform</title>
      <description>
        <![CDATA[The $180 million Caresyntax GmbH recently raised in a series C extension round allows the company to accelerate the commercialization and adoption of its precision surgery platform, Bjorn von Siemens, CFO and CBO of Caresyntax told BioWorld.]]>
      </description>
      <guid>http://www.bioworld.com/articles/711348</guid>
      <pubDate>Mon, 19 Aug 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/711348-caresyntax-raises-180m-to-grow-precision-surgery-platform</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Clinics/Clinical-data-illustration.webp?t=1621541773" type="image/png" medium="image" fileSize="381492">
        <media:title type="plain">Clinical data illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Asceneuron raises $100M for OGA inhibitor work in Alzheimer’s</title>
      <description>
        <![CDATA[Asceneuron SA has raised $100 million in an oversubscribed series C to take its lead small molecule, ASN-51, into phase II, with aim of demonstrating it prevents the formation of tau tangles and slows the progression of Alzheimer’s disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/710610</guid>
      <pubDate>Tue, 16 Jul 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710610-asceneuron-raises-100m-for-oga-inhibitor-work-in-alzheimers</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/NIH-NIA-Alzheimers-Abnormal-Tau.webp?t=1672942298" type="image/png" medium="image" fileSize="2087052">
        <media:title type="plain">Illustration of tau accumulating in a neuron cell.</media:title>
      </media:content>
    </item>
    <item>
      <title>Uromems raises $47M for smart automated artificial urinary sphincter</title>
      <description>
        <![CDATA[Uromems SAS raised $47 million in a series C financing round for its Uroactive system, the first smart automated artificial urinary sphincter device to treat stress urinary incontinence. With the funds the company will be able to “tackle the last stage of our clinical trials before commercial launch,” Hamid Lamraoui, CEO and co-founder of Uromems, told BioWorld.]]>
      </description>
      <guid>http://www.bioworld.com/articles/709643</guid>
      <pubDate>Thu, 27 Jun 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/709643-uromems-raises-47m-for-smart-automated-artificial-urinary-sphincter</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/UroActive-implant-male-27june24.webp?t=1719525906" type="image/jpeg" medium="image" fileSize="75147">
        <media:title type="plain">UroActive implant male</media:title>
        <media:description type="plain">UroActive device in male. Credit: Uromems</media:description>
      </media:content>
    </item>
    <item>
      <title>Endogenex raises $88M for Recet trial in T2D</title>
      <description>
        <![CDATA[Endogenex Inc. closed an oversubscribed $88 million series C financing round to support completion of its investigational device exemption trial for the Recet system. The Recet system uses non-thermal pulsed electric fields to remodel the duodenal tissue to treat adults with type 2 diabetes.]]>
      </description>
      <guid>http://www.bioworld.com/articles/709614</guid>
      <pubDate>Tue, 25 Jun 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/709614-endogenex-raises-88m-for-recet-trial-in-t2d</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/Endogenex-Recet-5-31.webp?t=1685569753" type="image/jpeg" medium="image" fileSize="123505">
        <media:title type="plain">Endogenex-Recet-5-31.jpg</media:title>
        <media:description type="plain">Endogenex Inc.’s ReCET procedure uses pulsed electrical field ablation to remodel the lining of the duodenum and increase insulin sensitivity in people with type 2 diabetes, allowing most to discontinue insulin.</media:description>
      </media:content>
    </item>
    <item>
      <title>Bright Peak Therapeutics raises funding to advance PD-1/IL-18 immunoconjugate into clinic</title>
      <description>
        <![CDATA[Bright Peak Therapeutics Inc. has raised $90 million in a series C financing. Proceeds will be used to accelerate a pipeline of next-generation immunotherapies and advance BPT-567 into a phase I/IIa trial.]]>
      </description>
      <guid>http://www.bioworld.com/articles/709364</guid>
      <pubDate>Tue, 11 Jun 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/709364-bright-peak-therapeutics-raises-funding-to-advance-pd-1-il-18-immunoconjugate-into-clinic</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cell-tumor-target.webp?t=1692022386" type="image/jpeg" medium="image" fileSize="543788">
        <media:title type="plain">3D illustration of cancer in crosshairs</media:title>
      </media:content>
    </item>
    <item>
      <title>Flying high with $182M, Bluejay Therapeutics advances BJT-778</title>
      <description>
        <![CDATA[Three years ago when Keting Chu pondered the name for a new biopharma company that would fold in infectious disease assets from Novartis AG, she looked out over her West Coast backyard. “I was looking for a name that made you think of California,” she told <em>BioWorld</em>. She nixed the idea of incorporating redwood trees into the name, but then she saw the blue jays flying around those trees and thought, “that’s a beautiful bird.” Hence, Chu founded and became CEO of Bluejay Therapeutics Inc., first raising $20 million through a series A in June 2021 and a $41 million series B in August 2022. On May 9, the San Mateo, Calif.-based company closed a $182 million series C round, with plans to accelerate development of lead compound BJT-778 to treat chronic hepatitis D virus, a condition for which there are no approved therapeutics in the U.S.]]>
      </description>
      <guid>http://www.bioworld.com/articles/708444</guid>
      <pubDate>Thu, 09 May 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/708444-flying-high-with-182m-bluejay-therapeutics-advances-bjt-778</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Newco/newco-plant-dollar-sign.webp?t=1588285768" type="image/png" medium="image" fileSize="378693">
        <media:title type="plain">Hand holding money plant</media:title>
      </media:content>
    </item>
    <item>
      <title>Memo boosts series C to CHF45M as BKV infection trial expands </title>
      <description>
        <![CDATA[Memo Therapeutics AG has added a further CHF20 million (US$22 million) to its series C, bringing the total for the round to CHF45 million and enabling the company to expand the phase II trial of its lead program, AntiBKV, in neutralizing BK virus infection in immune compromised kidney transplant recipients.]]>
      </description>
      <guid>http://www.bioworld.com/articles/708396</guid>
      <pubDate>Tue, 07 May 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/708396-memo-boosts-series-c-to-chf45m-as-bkv-infection-trial-expands</link>
    </item>
    <item>
      <title>Obexelimab’s one-two punch in IgG4 hooks $200M for Zenas</title>
      <description>
        <![CDATA[The bifunctional antibody approach continues to pay off for Zenas Biopharma Inc., which banked an upsized $200 million series C preferred stock financing led by SR One along with NEA, Norwest Venture Partners and Delos Capital. Enavate Sciences and Longitude Capital participated significantly as well.]]>
      </description>
      <guid>http://www.bioworld.com/articles/708390</guid>
      <pubDate>Tue, 07 May 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/708390-obexelimabs-one-two-punch-in-igg4-hooks-200m-for-zenas</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Antibodies1.webp?t=1602525470" type="image/png" medium="image" fileSize="462467">
        <media:title type="plain">Antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>$182M for Sionna’s ‘new standard of care’ in cystic fibrosis</title>
      <description>
        <![CDATA[Sionna Therapeutics Inc.’s approach with small molecules in cystic fibrosis (CF) yielded the Boston-based firm an upsized and oversubscribed $182 million series C financing. The company is working on drugs that could fully restore the function of the CF transmembrane conductance regulator protein by stabilizing the first nucleotide-binding domain (NBD1). Four compounds are expected to enter the clinic this year – three NBD1 stabilizers and one ICL4 modulator.]]>
      </description>
      <guid>http://www.bioworld.com/articles/706362</guid>
      <pubDate>Wed, 06 Mar 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/706362-182m-for-sionnas-new-standard-of-care-in-cystic-fibrosis</link>
    </item>
  </channel>
</rss>
